BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12677027)

  • 1. Clinical research. A setback and an advance on the AIDS vaccine front.
    Cohen J
    Science; 2003 Apr; 300(5616):28-9. PubMed ID: 12677027
    [No Abstract]   [Full Text] [Related]  

  • 2. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 3. Thailand's Prime-Boost HIV Vaccine Phase III.
    Trinvuthipong C
    Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 7. Prime-boost immunization strategies against HIV.
    Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV adenovirus vaccine in Phase I trials.
    Expert Rev Vaccines; 2003 Aug; 2(4):471. PubMed ID: 14711332
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV vaccine may raise risk.
    Ledford H
    Nature; 2007 Nov; 450(7168):325. PubMed ID: 18004331
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 14. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
    Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
    J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outstanding questions on HIV vaccine trial.
    Jefferys R; Harrington M
    Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
    [No Abstract]   [Full Text] [Related]  

  • 17. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV/AIDS research. Surprising AIDS vaccine success praised and pondered.
    Cohen J
    Science; 2009 Oct; 326(5949):26-7. PubMed ID: 19797628
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccines for control of HIV infections.
    Sharma KB
    J Indian Med Assoc; 1994 Jan; 92(1):27-8. PubMed ID: 8207277
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV/AIDS. Hedged bet: an unusual AIDS vaccine trial.
    Cohen J
    Science; 2005 Aug; 309(5737):1003. PubMed ID: 16099960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.